Bayer Signs a Clinical Collaboration Agreement with BMS and Ono to Evaluate Dual Regimen for Metastatic Colorectal Cancer
Shots:
- Bayer- BMS and Ono collaborate to evaluate the combination of Bayer’s Stivarga (regorafenib) with BMS & Ono’s Opdivo (nivolumab) vs regorafenib in patients with micro-satellite stable mCRC
- The collaboration follows safety data of regorafenib as 3L monothx. in P-III CORRECT study and the efficacy data of P-I REGONIVO study evaluating the combination of regorafenib and nivolumab in Japan
- Stivarga is an oral multi-kinase inhibitor targeting angiogenic- stromal and oncogenic receptor tyrosine kinase and is an approved therapy for patients with hepatocellular carcinoma prior treated with Nexavar. Opdivo is a PD-1 immune checkpoint inhibitor harnessing the body’s own immune system against cancer
Click here to read full press release/ article
Ref: BMS | Image: BMS
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com